Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733–45. doi:10.1056/NEJM199712113372406.

    Article  CAS  PubMed  Google Scholar 

  2. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136(5):699–712. doi:10.1111/j.1365-2141.2006.06465.x.

    Article  CAS  PubMed  Google Scholar 

  3. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307. doi:10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0.

    Article  CAS  PubMed  Google Scholar 

  4. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.

    CAS  PubMed  Google Scholar 

  5. Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8(Suppl 1):107–9. doi:10.1023/A:1008234807768.

    Article  PubMed  Google Scholar 

  6. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70(4):553–61. doi:10.1002/jmv.10430.

    Article  PubMed  Google Scholar 

  7. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;246:540–6.

    Article  Google Scholar 

  8. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37(10):705–12.

    CAS  PubMed  Google Scholar 

  9. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999;81(1):69–74. doi:10.1038/sj.bjc.6690652.

    Article  CAS  PubMed  Google Scholar 

  10. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209–20. doi:10.1002/hep.21051.

    Article  CAS  PubMed  Google Scholar 

  11. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation inpatients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270–5. doi:10.1007/s00277-003-0825-8.

    Article  CAS  PubMed  Google Scholar 

  12. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005;28(4):379–84. doi:10.1097/01.coc.0000159554.97885.88.

    Article  PubMed  Google Scholar 

  13. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(4):385–7. doi:10.1023/A:1008206519571.

    Article  CAS  PubMed  Google Scholar 

  14. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306–11. doi:10.1038/sj.bjc.6601699.

    Article  CAS  PubMed  Google Scholar 

  15. Hsu CH, Hsu HC, Chen HL, et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 2004;24(5A):3035–40.

    CAS  PubMed  Google Scholar 

  16. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA. 1986;83(6):1627–31. doi:10.1073/pnas.83.6.1627.

    Article  CAS  PubMed  Google Scholar 

  17. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–9. doi:10.1053/j.gastro.2003.09.026.

    Article  CAS  PubMed  Google Scholar 

  18. Gish RG, Locarnini S. Studying the treatment of chronic hepatitis B viral infection in special populations. Methods Mol Med. 2004;96:465–98.

    CAS  PubMed  Google Scholar 

  19. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009–22. doi:10.1053/gast.2001.22461.

    Article  CAS  PubMed  Google Scholar 

  20. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer. 1996;78(10):2210–5. doi:10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0.

    Article  CAS  PubMed  Google Scholar 

  21. Cheng AL, Hsiung CA, Su IJ, et al. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320–8. doi:10.1053/jhep.2003.50220.

    Article  CAS  PubMed  Google Scholar 

  22. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol. 2006;21(4):299–305. doi:10.1007/s10654-006-0001-2.

    Article  PubMed  Google Scholar 

  23. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394–8.

    CAS  PubMed  Google Scholar 

  24. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001;65(3):473–7. doi:10.1002/jmv.2060.

    Article  CAS  PubMed  Google Scholar 

  25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569–83. doi:10.1093/annonc/mdi326.

    Article  CAS  PubMed  Google Scholar 

  26. Conlin AK, Seidman AD. Taxanes in breast cancer: an update. Curr Oncol Rep. 2007;9(1):22–30. doi:10.1007/BF02951422.

    Article  CAS  PubMed  Google Scholar 

  27. Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12(3):191–6. doi:10.1007/s00520-003-0549-2.

    Article  PubMed  Google Scholar 

  28. Cheng JC, Liu MC, Tsai SY, Fang WT, Jer-Min Jian J, Sung JL. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer. 2004;101(9):2126–33. doi:10.1002/cncr.20591.

    Article  PubMed  Google Scholar 

  29. Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. doi:10.1056/NEJMoa010187.

    Article  CAS  PubMed  Google Scholar 

  30. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115(1):58–62. doi:10.1046/j.1365-2141.2001.03099.x.

    Article  CAS  PubMed  Google Scholar 

  31. Simpson ND, Simpson PW, Ahmed AM, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine. J Clin Gastroenterol. 2003;37(1):68–71. doi:10.1097/00004836-200307000-00017.

    Article  CAS  PubMed  Google Scholar 

  32. Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut. 2006;55(8):1208–9.

    CAS  PubMed  Google Scholar 

  33. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89–102.

    CAS  PubMed  Google Scholar 

  34. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–28.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Medical Oncology, Selcuk University Meram Medical Faculty, Konya, Turkey

    Orhan Onder Eren, Mehmet Artac, Melih Cem Boruban & Ozlem Yavas

  2. Department of Microbiology, Selcuk University Meram Medical Faculty, Konya, Turkey

    Ugur Arslan

  3. Department of Internal Medicine, Division of Gastroenterology, Selcuk University Meram Medical Faculty, Konya, Turkey

    Metin Basaranoglu

Authors
  1. Orhan Onder Eren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Artac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melih Cem Boruban
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ozlem Yavas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ugur Arslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Metin Basaranoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Artac.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eren, O.O., Artac, M., Boruban, M.C. et al. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. Med Oncol 26, 386–392 (2009). https://doi.org/10.1007/s12032-008-9133-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-008-9133-4

Keywords

Search

Navigation